Retrophin Inc Institutional Investor Sentiment Increased in Q2 2018

Retrophin, Inc. (NASDAQ:RTRX) Logo

Sentiment for Retrophin Inc (NASDAQ:RTRX)

Retrophin Inc (NASDAQ:RTRX) institutional sentiment increased to 1.32 in Q2 2018. Its up 0.08, from 1.24 in 2018Q1. The ratio has improved, as 62 hedge funds increased and started new equity positions, while 47 sold and decreased their positions in Retrophin Inc. The hedge funds in our partner’s database now possess: 40.01 million shares, up from 39.72 million shares in 2018Q1. Also, the number of hedge funds holding Retrophin Inc in their top 10 equity positions was flat from 2 to 2 for the same number . Sold All: 10 Reduced: 37 Increased: 37 New Position: 25.

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. The company has market cap of $990.77 million. The Company’s marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. It currently has negative earnings. The companyÂ’s product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc , a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.

The stock decreased 2.24% or $0.55 during the last trading session, reaching $24.02. About 432,461 shares traded or 30.70% up from the average. Retrophin, Inc. (NASDAQ:RTRX) has risen 24.42% since December 8, 2017 and is uptrending. It has outperformed by 8.80% the S&P500.

Analysts await Retrophin, Inc. (NASDAQ:RTRX) to report earnings on February, 26. They expect $-0.62 earnings per share, down 58.97 % or $0.23 from last year’s $-0.39 per share. After $-1.34 actual earnings per share reported by Retrophin, Inc. for the previous quarter, Wall Street now forecasts -53.73 % EPS growth.

Consonance Capital Management Lp holds 6.76% of its portfolio in Retrophin, Inc. for 3.84 million shares. Broadfin Capital Llc owns 1.05 million shares or 4.5% of their US portfolio. Moreover, Perceptive Advisors Llc has 1.5% invested in the company for 3.21 million shares. The Israel-based Sphera Funds Management Ltd. has invested 1.33% in the stock. Falcon Point Capital Llc, a California-based fund reported 137,376 shares.

Since January 1, 0001, it had 0 buys, and 6 insider sales for $1.31 million activity.

Retrophin, Inc. (NASDAQ:RTRX) Ratings Coverage

Ratings analysis reveals 100% of Retrophin’s analysts are positive. Out of 3 Wall Street analysts rating Retrophin, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $36 while the high is $57. The stock’s average target of $45.67 is 90.13% above today’s ($24.02) share price. RTRX was included in 3 notes of analysts from August 17, 2018.

More notable recent Retrophin, Inc. (NASDAQ:RTRX) news were published by: Globenewswire.com which released: “Retrophin to Present at the Jefferies 2018 London Healthcare Conference – GlobeNewswire” on November 07, 2018, also Globenewswire.com with their article: “Retrophin Announces Proposed Convertible Senior Notes Offering – GlobeNewswire” published on September 04, 2018, Globenewswire.com published: “Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology – GlobeNewswire” on October 25, 2018. More interesting news about Retrophin, Inc. (NASDAQ:RTRX) were released by: Seekingalpha.com and their article: “15 years in prison for Shkreli? – Seeking Alpha” published on March 07, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For November 19, 2018 – Benzinga” with publication date: November 19, 2018.

Retrophin, Inc. (NASDAQ:RTRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.